此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

LY4170156 在选定的晚期实体瘤参与者中的研究

2026年11月3日 更新者:Eli Lilly and Company

一项首次人体 1a/1b 期试验,旨在评估 LY4170156(一种针对表达叶酸受体 α 的肿瘤细胞的抗体药物偶联物)在选定的晚期实体瘤参与者中的安全性、耐受性和初步疗效

The purpose of this study is to find out whether the study drug, Sofetabart Mipitecan (LY4170156), is safe, tolerable and effective in participants with advanced solid tumors. The study is conducted in three parts - phase Ia (dose-escalation, dose-optimization), phase Ib (dose-expansion), and phase 2 (dose expansion). The study will last up to approximately 5 years.

研究概览

研究类型

介入性

注册 (估计的)

575

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

  • 姓名:Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
  • 电话号码:1-317-615-4559
  • 邮箱:LillyTrials@Lilly.com

研究联系人备份

学习地点

      • Milan、意大利、20141
        • 招聘中
        • Istituto Europeo di Oncologia
        • 首席研究员:
          • Giuseppe Curigliano
        • 接触:
          • 电话号码:+39 02 5748 9599
      • Milan、意大利、20159
        • 招聘中
        • Humanitas San Pio X
        • 首席研究员:
          • Domenica Lorusso
      • Shizuoka、日本、411-8777
        • 招聘中
        • Shizuoka Cancer Center
        • 接触:
          • 电话号码:81120023812
        • 首席研究员:
          • Haruyasu Murakami
      • Tokyo、日本、104-0045
        • 招聘中
        • National Cancer Center Hospital
        • 接触:
          • 电话号码:81120023812
        • 首席研究员:
          • Takafumi Koyama
      • Tokyo、日本、135-8550
        • 招聘中
        • Cancer Institute Hospital of JFCR
        • 首席研究员:
          • Shigehisa Kitano
        • 接触:
          • 电话号码:81120023812
      • Lyon、法国、69373
        • 招聘中
        • Centre Leon Berard
        • 首席研究员:
          • Isabelle Ray-Coquard
        • 接触:
          • 电话号码:+33478782644
      • Saint-Herblain、法国、44805
        • 招聘中
        • Institut de Cancerologie de l'Ouest - site St-Herblain
        • 首席研究员:
          • Mario Campone
        • 接触:
          • 电话号码:+33 02 40 67 99 00
      • Toulouse、法国、31059
        • 招聘中
        • Oncopole Claudius Regaud
        • 首席研究员:
          • Carlos Gomez-Roca
      • Adelaide、澳大利亚、5000
        • 招聘中
        • Cancer Research SA
        • 首席研究员:
          • Meena Okera
      • QLD、澳大利亚、4101
        • 招聘中
        • Icon Cancer Centre South Brisbane
        • 首席研究员:
          • Jermaine Coward
    • Arizona
      • Scottsdale、Arizona、美国、85258
        • 招聘中
        • HonorHealth
        • 接触:
          • 电话号码:480-323-1350
        • 首席研究员:
          • Muhammad Khawaja
    • California
      • La Jolla、California、美国、92037
        • 招聘中
        • University of California, San Diego (UCSD) - Moores Cancer Center
        • 首席研究员:
          • Ramez Eskander
        • 接触:
          • 电话号码:858-657-7000
    • Georgia
      • Atlanta、Georgia、美国、30308
        • 招聘中
        • Emory University
        • 首席研究员:
          • Beryl Manning-Geist
    • Michigan
      • Grand Rapids、Michigan、美国、49546
        • 招聘中
        • South Texas Accelerated Research Therapeutics (START) Midwest
        • 首席研究员:
          • Nehal Lakhani
        • 接触:
          • 电话号码:616-389-1652
    • New York
      • Mineola、New York、美国、11501
        • 招聘中
        • NYU Langone Health - Long Island
        • 首席研究员:
          • Bhavana Pothuri
      • New York、New York、美国、10065
        • 招聘中
        • David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center
        • 首席研究员:
          • Chrisann Kyi
      • New York、New York、美国、10016
        • 招聘中
        • New York University (NYU) Clinical Cancer Center
        • 首席研究员:
          • Bhavana Pothuri
        • 接触:
          • 电话号码:212-731-5100
    • Ohio
      • Columbus、Ohio、美国、43210
        • 招聘中
        • The Ohio State University (OSU) Wexner Medical Center
        • 首席研究员:
          • David O'Malley
    • Texas
      • Houston、Texas、美国、77030-4000
        • 招聘中
        • The University of Texas - MD Anderson Cancer Center
        • 首席研究员:
          • Shannon Westin
    • Utah
      • West Valley City、Utah、美国、84119
        • 招聘中
        • START Mountain Region
        • 首席研究员:
          • William McKean
    • Virginia
      • Falls Church、Virginia、美国、22042
        • 尚未招聘
        • Inova Schar Cancer Institute
        • 首席研究员:
          • Leslie Randall
      • Barcelona、西班牙、08035
        • 招聘中
        • Hospital Universitario Vall d'Hebron
        • 接触:
          • 电话号码:+34 932543450
        • 首席研究员:
          • Roberta Mazzeo
      • Madrid、西班牙、28041
        • 招聘中
        • Hospital Universitario 12 de Octubre
        • 接触:
          • 电话号码:+34 913908922
        • 首席研究员:
          • Ainhoa Madariaga Urrutia
      • Valencia、西班牙、46010
        • 招聘中
        • Hospital Clinico Universitario de Valencia
        • 首席研究员:
          • Jose Alejandro Perez Fidalgo
        • 接触:
          • 电话号码:+34 961973527
      • Goyang-si Gyeonggi-do、韩国、10408
        • 招聘中
        • National Cancer Center
        • 首席研究员:
          • Myong Cheol Lim
        • 接触:
          • 电话号码:82-1588-8110

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Have one of the following solid tumor cancers:

    • Dose Escalation: Ovarian (epithelial ovarian, primary peritoneal, and fallopian tube) cancer, endometrial cancer, cervical cancer, non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), pancreatic cancer, or colorectal cancer (CRC)
    • Dose Optimization: Ovarian (epithelial ovarian, primary peritoneal, and fallopian tube) and endometrial cancer
    • Dose Expansion: Low grade serous ovarian cancer, cervical cancer, NSCLC, TNBC, and high grade endometrioid cancer

Exclusion Criteria:

  • Individual with known or suspected uncontrolled central nervous system (CNS) metastases
  • Individual with history of carcinomatous meningitis
  • Individual with active uncontrolled systemic bacterial, viral, fungal, or parasitic infection
  • Individual with evidence of corneal keratopathy or history of corneal transplant
  • Any serious unresolved toxicities from prior therapy
  • Significant cardiovascular disease
  • Prolongation of QT interval corrected for heart rate using Fridericia's formula (QTcF) ≥ 470 milliseconds (ms)
  • History of pneumonitis/interstitial lung disease
  • Individuals who are pregnant, breastfeeding or plan to breastfeed during study or within 30 days of last dose of study intervention

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Sofe-M (Dose-escalation, Cohort A1)

Escalating doses of Sofe-M administered intravenously (IV)

Intravenous

其他名称:
  • 索非他巴特米哌替康
  • LY4170156
实验性的:Sofe-M (Cohort A1 Parts A and C)

Sofe-M administered IV

Intravenous

其他名称:
  • 索非他巴特米哌替康
  • LY4170156
实验性的:Sofe-M Alone or with Itraconazole. Drug-Drug Interaction (DDI) (Cohort A1: Arm B)

Sofe-M administered IV and itraconazole administered orally

Intravenous

其他名称:
  • 索非他巴特米哌替康
  • LY4170156

oral

实验性的:Sofe-M (Dose-optimization, Cohort A2)

Comparing 2 or more doses (evaluated during dose escalation) of Sofe-M administered IV

Intravenous

其他名称:
  • 索非他巴特米哌替康
  • LY4170156
实验性的:Sofe-M (Enrichment Cohort A3)

Monotherapy administered IV

Intravenous

其他名称:
  • 索非他巴特米哌替康
  • LY4170156
实验性的:Sofe-M (Combination Cohort A4)

Combination with bevacizumab administered IV

Intravenous

其他名称:
  • 索非他巴特米哌替康
  • LY4170156

IV

实验性的:Sofe-M (Combination Cohort A5)

Combination with carboplatin administered IV

Intravenous

其他名称:
  • 索非他巴特米哌替康
  • LY4170156

IV

实验性的:Sofe-M Combination with Pembrolizumab (Dose-optimization Cohort A6)

Comparing 2 or more doses (evaluated during dose escalation) of Sofe-M administered IV with pembrolizumab

Intravenous

其他名称:
  • 索非他巴特米哌替康
  • LY4170156

IV

实验性的:Sofe-M Combination with carboplatin and optional bevacizumab (Dose-optimization Cohort A7)

Comparing 2 or more doses (evaluated during dose escalation) of Sofe-M administered IV with or without bevacizumab

Intravenous

其他名称:
  • 索非他巴特米哌替康
  • LY4170156

IV

IV

实验性的:Sofe-M (Dose-expansion, Cohort B2-B4)

Sofe-M administered IV

Intravenous

其他名称:
  • 索非他巴特米哌替康
  • LY4170156
实验性的:Sofe-M (Dose-expansion, Cohort B1)

Sofe-M administered IV

Intravenous

其他名称:
  • 索非他巴特米哌替康
  • LY4170156

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Phase 1a: To determine the recommended phase 2 dose (RP2D) of Sofe-M (LY4170156)
大体时间:1 Cycle (21 or 28 days)

Number of participants with dose-limiting toxicities (DLTs)

1 Cycle (21 or 28 days)
Phase 1a: To determine the RP2D or optimal dose of Sofe-M (LY4170156) with bevacizumab
大体时间:1 Cycle (21 or 28 days)

Number of participants with DLTs

1 Cycle (21 or 28 days)
Phase 1a: To determine the RP2D or optimal dose of Sofe-M (LY4170156) with carboplatin
大体时间:1 Cycle (21 or 28 days)

Number of participants with DLTs

1 Cycle (21 or 28 days)
Phase 1a: To determine the RP2D or optimal dose of Sofe-M (LY4170156) with pembrolizumab
大体时间:1 Cycle (21 or 28 days)

Number of participants with DLTs

1 Cycle (21 or 28 days)
Phase 1b: To assess the antitumor activity of Sofe-M (LY4170156) Monotherapy: Overall response rate (ORR)
大体时间:Up to Approximately 60 Months or 5 Years

ORR per investigator assessed Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1)

Up to Approximately 60 Months or 5 Years
Phase 2: To assess the antitumor activity of Sofe-M (LY4170156) Monotherapy: ORR
大体时间:Up to Approximately 60 Months or 5 Years

ORR per RECIST 1.1

Up to Approximately 60 Months or 5 Years
Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
大体时间:Up to Approximately 60 Months or 5 Years

A summary of SAEs regardless of causality, will be reported in the Reported Adverse Events module

Up to Approximately 60 Months or 5 Years

次要结果测量

结果测量
措施说明
大体时间
To characterize the pharmacokinetics (PK) properties of Sofe-M (LY4170156): Minimum Plasma Concentration (Cmin)
大体时间:First 4 Cycles (84 days)

PK: Cmin of Sofe-M (LY4170156)

First 4 Cycles (84 days)
To characterize the PK properties of Sofe-M (LY4170156): Cmin with bevacizumab or carboplatin
大体时间:First 4 Cycles (Approximately 84 days)

PK: Cmin of Sofe-M (LY4170156)

First 4 Cycles (Approximately 84 days)
To characterize the PK properties of Sofe-M (LY4170156): Cmin with pembrolizumab
大体时间:First 4 Cycles (84 days)

PK: Cmin of Sofe-M (LY4170156)

First 4 Cycles (84 days)
To characterize the PK properties of Sofe-M (LY4170156): Area under the concentration versus time curve (AUC)
大体时间:First 4 Cycles (84 days)

PK: AUC of Sofe-M (LY4170156)

First 4 Cycles (84 days)
To characterize the patient-reported outcomes (PRO) Common Terminology Criteria for Adverse Events (CTCAE) of Sofe-M (LY4170156)
大体时间:Up to Approximately 60 Months or 5 Years

PRO-CTCAE of Sofe-M (LY4170156)

Up to Approximately 60 Months or 5 Years
To evaluate the preliminary antitumor activity of Sofe-M (LY4170156): Overall response rate (ORR)
大体时间:Up to Approximately 60 Months or 5 Years

ORR per investigator assessed Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1)

Up to Approximately 60 Months or 5 Years
To evaluate the preliminary antitumor activity of Sofe-M (LY4170156): Overall response rate (ORR) with bevacizumab or carboplatin or pembrolizumab
大体时间:Up to Approximately 60 Months or 5 Years

ORR per investigator assessed Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1)

Up to Approximately 60 Months or 5 Years
To evaluate the preliminary antitumor activity of Sofe-M (LY4170156): Duration of response (DOR)
大体时间:Up to Approximately 60 Months or 5 Years

DOR per investigator assessed RECIST 1.1

Up to Approximately 60 Months or 5 Years
To evaluate the preliminary antitumor activity of Sofe-M (LY4170156): Duration of response (DOR) with bevacizumab or carboplatin or pembrolizumab
大体时间:Up to Approximately 60 Months or 5 Years

DOR per investigator assessed RECIST 1.1

Up to Approximately 60 Months or 5 Years
To evaluate the preliminary antitumor activity of Sofe-M (LY4170156): Time to response (TTR)
大体时间:Up to Approximately 60 Months or 5 Years

TTR per investigator assessed RECIST 1.1

Up to Approximately 60 Months or 5 Years
To evaluate the preliminary antitumor activity of Sofe-M (LY4170156): Time to response (TTR) with bevacizumab or carboplatin or pembrolizumab
大体时间:Up to Approximately 60 Months or 5 Years

TTR per investigator assessed RECIST 1.1

Up to Approximately 60 Months or 5 Years
To evaluate the preliminary antitumor activity of Sofe-M (LY4170156): Progression free survival (PFS)
大体时间:Up to Approximately 60 Months or 5 Years

PFS per investigator assessed RECIST 1.1

Up to Approximately 60 Months or 5 Years
To evaluate the preliminary antitumor activity of Sofe-M (LY4170156): Progression free survival (PFS) with bevacizumab or carboplatin or pembrolizumab
大体时间:Up to Approximately 60 Months or 5 Years]

PFS per investigator assessed RECIST 1.1

Up to Approximately 60 Months or 5 Years]
To evaluate the preliminary antitumor activity of Sofe-M (LY4170156): Disease control rate (DCR)
大体时间:Up to Approximately 60 Months or 5 Years

DCR per investigator assessed RECIST 1.1

Up to Approximately 60 Months or 5 Years
To evaluate the preliminary antitumor activity of Sofe-M (LY4170156): Disease control rate (DCR) with bevacizumab or carboplatin or pembrolizumab
大体时间:Up to Approximately 60 Months or 5 Years

DCR per investigator assessed RECIST 1.1

Up to Approximately 60 Months or 5 Years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)、Eli Lilly and Company

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年5月20日

初级完成 (估计的)

2029年6月1日

研究完成 (估计的)

2029年6月1日

研究注册日期

首次提交

2024年4月30日

首先提交符合 QC 标准的

2024年5月1日

首次发布 (实际的)

2024年5月6日

研究记录更新

最后更新发布 (实际的)

2026年11月4日

上次提交的符合 QC 标准的更新

2026年11月3日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

IPD 共享时间框架

Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

IPD 共享访问标准

A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

IPD 共享支持信息类型

  • 研究方案
  • 树液
  • 企业社会责任

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅